Expanded Portfolio for Biomolecules Purification Announced

With the increased interest in the purification of a wider variety of biomolecules, the portfolio of Kromasil 300 Å has been expanded to support these applications.

The Kromasil 300 Å line of HPLC products is now shipping with C18, C8, C4 and diC4 derivatisations for scientists and engineers exploiting selectivity and loadability for purification of API and impurity isolation. In particular, the new Kromasil 300 Å diC4 has different characteristic than a classic C4, enabling new opportunities to remove impurities from peptide and protein crudes.

For more information, visit www.kromasil.com